Table 3 Estimated treatment effects on mean survival and CVD-free time and HRs by treatment group for all approaches: LAC-IPWRA and adjusted HRs by Weibull regression with PS adjustment
Treatments | OS | Time to CVD | ||
|---|---|---|---|---|
Mean OS (LAC-IPWRA) | Adjusted HR (Conventional PS) | Mean CVD-free time (LAC-IPWRA) | Adjusted HR (Conventional PS) | |
ITT approach | ||||
 No-PBs | 11.17 (9.57, 12.76) | 1 (ref) | 8.54 (7.28, 13.43) | 1 (ref) |
 CBPBs | 11.45 (10.03, 12.87) | 0.96 (0.77, 0.99) | 13.76 (10.93, 16.48) | 0.95 (0.86, 1.05) |
 NCBPBs | 28.24 (-22.58, 79.06) | 0.87 (0.69, 1.30) | 22.74 (-24.57, 99.04) | 0.68 (0.45, 1.03) |
 Aluminum hydroxide | 7.26 (3.33, 11.18) | 1.08 (0.80, 1.45) | 47.65 (-41.55, 136.85) | 0.99 (0.67, 1.45) |
PPA approach | ||||
 No-PBs | 10.13 (9.14, 11.07) | 1 (ref) | 8.57 (7.89, 9.25) | 1 (ref) |
 CBPBs | 10.68 (8.98, 11.59) | 0.90 (0.87, 1.08) | 9.09 (7.75, 12.21) | 0.97 (0.87, 1.08) |
 NCBPBs | 12.38 (-27.21, 45.22) | 0.86 (0.54, 1.46) | 17.69 (-22.27, 79.65) | 0.68 (0.36, 1.27) |
 Aluminum hydroxide | excluded | excluded | excluded | excluded |
Actual treatment-patterns approach | ||||
 No-PBs | 10.42 (9.94, 11.20) | 1 (ref) | 8.19 (5.67, 8.97) | 1 (ref) |
 CBPBs-CBPBs | 10.86 (8.46, 11.96) | 0.91 (0.79, 1.01) | 9.84 (6.18, 12.36) | 0.84 (0.56, 1.08) |
 CBPBs-NCBPBs | 13.49 (10.03, 16.93) | 0.77 (0.58, 1.16) | 11.27 (6.83, 15.91) | 0.77 (0.45, 1.06) |
 CBPBs-Aluminum | 11.01 (7.54, 14.48) | 0.92 (0.70, 1.32) | 75.96 (-50.61, 184.53) | 1.39 (0.85, 2.25) |